Matt Gline, Roivant Sciences CEO (Photo by John Sciulli/Getty Images for GLG)

Pfiz­er and Roivant team up again for an­oth­er 'Van­t', set­ting up an­ti-in­flam­ma­to­ry show­down with Prometheus

Pfiz­er and Roivant are team­ing up to launch a new ‘Vant’ aimed at bring­ing a mid-stage an­ti-in­flam­ma­to­ry drug to mar­ket, the pair an­nounced Thurs­day.

There’s no name for the start­up yet, nor are there any em­ploy­ees. Thus far, the new com­pa­ny and Roivant can be con­sid­ered “one and the same,” Roivant CEO Matt Gline tells End­points News. But Pfiz­er is so en­thu­si­as­tic about the tar­get that it elect­ed to keep 25% of eq­ui­ty in the drug rather than take up­front cash from Roivant, Gline said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.